Last week’s fifth annual HLTH conference in Las Vegas was the biggest and boldest yet. The event was overflowing with interesting information and innovative ideas that push to define healthcare for the next decade. Many of the topics discussed tie directly to the work we do at Decode Health. Here are our team’s takeaways.
We’re excited to announce the BD and Decode Health strategic partnership that will accelerate innovation and advance precision medicine. Together, we’re working to advance at home collections for molecular biomarkers like RNA using a simple finger stick. Our work could unlock groundbreaking innovations for biomarker discovery and routine screening across multiple disciplines from oncology to autoimmune diseases and beyond. At-home testing can significantly improve efficiency and enhance diversity in clinical trials, speeding the development of potentially life-saving treatments.
Decode Health, a healthcare AI company that enables a partner ecosystem to innovate and solve data challenges involving disease risk, today announced a new phase of its collaboration with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, to empower drug and diagnostics research and development in the growing fields of metabolic disease and autoimmune neurology.
Decode Health, a rapidly growing healthcare AI company that enables a partner ecosystem to innovate and solve data challenges involving disease risk, announced today that two healthcare industry veterans will expand their current advisory roles within the company.
Decode Health was recently recognized with an AI Innovator Award at the DataRobot AIX 22 global virtual conference. DataRobot is a Boston-based AI cloud platform company that works with customers worldwide across industries and verticals, including almost 40% of Fortune 50 companies.
Autoimmune diseases, such as multiple sclerosis (MS), ulcerative colitis, Crohn’s disease, and rheumatoid arthritis, are complex diseases that affect over four million people in the United States and cost the healthcare system over $90 billion [read more...]
The SARS-CoV-2 (COVID-19) pandemic has exposed health disparities throughout the USA, particularly among racial and ethnic minorities. As a result, there is a need for data-driven approaches to pinpoint the unique constellation of clinical and social determinants of health (SDOH) risk factors that give rise to poor patient outcomes following infection in US communities.
The SARS-CoV-2 (COVID-19) pandemic has exposed the need to understand the risk drivers that contribute to uneven morbidity and mortality in US communities. Addressing the community-specific social determinants of health (SDOH) that correlate with spread of SARS-CoV-2 provides an opportunity for targeted public health intervention to promote greater resilience to viral respiratory infections.
According to an article in the Journal of the American Medical Association (JAMA), two Harvard economists estimate the cumulative financial costs of the COVID-19 pandemic at more than $16 trillion. To put this number into perspective, that’s approximately 90% of annual GDP of the United States or $200,000 for a family of four. This is a combination of lost income due to the COVID-induced recession and the economic effect of a shorter, less healthy life.
Just as national health officials warned ahead of the holiday season, the winter months of 2020-21 have proven to be the most challenging period of the COVID-19 pandemic so far. In Tennessee alone, there have [read more...]
